Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Collect systematic data on mental health, quality of life (QOL), social support, diet, and exercise behaviors in melanoma patients.
II. Examine whether psychosocial factors and lifestyle are associated with clinical outcomes in melanoma patients.
III. Examine the association between lifestyle and psychosocial factors and tissue and blood biomarkers in melanoma patients.
IV. Examine whether psychosocial factors and lifestyle are associated with QOL adjustment in melanoma patients.
OUTLINE:
Patients complete a maximum of 3 paper or electronic questionnaires over 30 minutes within 2 weeks of presentation to MD Anderson, new diagnosis of melanoma, and/or initiating a new treatment, within 2 weeks of first restaging, and within 2 weeks of the end of treatment. Patients may complete an additional paper or electronic dietary questionnaire over 10 minutes for 3 days (30 minutes total) or a phone-based dietary recall. Patients who start a new treatment of interest may repeat the questionnaires at the same time points. Patients' medical records are also reviewed.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Carrie Daniel-MacDougall
- Phone Number: 713-563-5783
- Email: cdaniel@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Contact:
- Carrie Daniel-MacDougall
- Phone Number: 713-563-5783
- Email: cdaniel@mdanderson.org
-
Principal Investigator:
- Carrie Daniel-MacDougall
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of melanoma, precursor lesions, and associated cutaneous pathology
- Able to read and understand English
- Willing to complete an online or paper survey
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Observational (questionnaire, medical chart review)
Patients complete a maximum of 3 paper or electronic questionnaires over 30 minutes within 2 weeks of presentation to MD Anderson, new diagnosis of melanoma, and/or initiating a new treatment, within 2 weeks of first restaging, and within 2 weeks of the end of treatment.
Patients may complete an additional paper or electronic dietary questionnaire over 10 minutes for 3 days (30 minutes total) or a phone-based dietary recall.
Patients who start a new treatment of interest may repeat the questionnaires at the same time points.
Patients' medical records are also reviewed.
|
Complete questionnaires
Medical charts are reviewed
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in depression/distress
Time Frame: Up to 10 years
|
Will be assessed using the Centers for Epidemiologic Studies - Depression.
Lifetime history of Major Depressive Disorder (MDD) will be measured using the two cardinal items from the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders-IV Disorder.
Multivariate methods, including repeated measures analyses, will be employed to further explore the potential changes in the measures over time.
|
Up to 10 years
|
|
Change in anxiety
Time Frame: Up to 10 years
|
Will be assessed using the Speilberger State/Trait Anxiety Inventory.
Multivariate methods, including repeated measures analyses, will be employed to further explore the potential changes in the measures over time.
|
Up to 10 years
|
|
Change in cancer-related symptoms
Time Frame: Up to 10 years
|
Will be assessed using the MD Anderson Symptom Inventory.
Multivariate methods, including repeated measures analyses, will be employed to further explore the potential changes in the measures over time.
|
Up to 10 years
|
|
Change in social support
Time Frame: Up to 10 years
|
Will be assessed using the 24-item Social Provisions Scale.
Multivariate methods, including repeated measures analyses, will be employed to further explore the potential changes in the measures over time.
|
Up to 10 years
|
|
Change in general eating habits
Time Frame: Up to 10 years
|
Will be assessed using the National Cancer Institute National Health and Nutrition Examination Survey Dietary Screener Questionnaire, and optionally, the National Institutes of Health Automated Self-Administered 24-hour.
|
Up to 10 years
|
|
Change in physical activity
Time Frame: Up to 10 years
|
Will be assessed using the Godin Leisure -Time Exercise Questionnaire.
Multivariate methods, including repeated measures analyses, will be employed to further explore the potential changes in the measures over time.
|
Up to 10 years
|
|
Associations between mental health, social support, diet and exercise behaviors, and quality of life and demographic variables
Time Frame: Up to 10 years
|
Will be evaluated using Pearson's product moment correlation coefficients together with scatterplots where appropriate.
|
Up to 10 years
|
|
Effect of diet, physical activity, depressive symptoms, distress, lifetime MDD, and social support on progression free survival
Time Frame: Up to 10 years
|
Will be evaluated using Pearson's product moment correlation coefficients together with scatterplots where appropriate.
|
Up to 10 years
|
|
Effect of diet, physical activity, depressive symptoms, distress, lifetime MDD, and social support on cancer mortality
Time Frame: Up to 10 years
|
Will be evaluated using Pearson's product moment correlation coefficients together with scatterplots where appropriate.
|
Up to 10 years
|
|
Response to treatment
Time Frame: Up to 10 years
|
Logistic regression models will be used to measure the association of diet, physical activity, diet, depressive symptoms, distress, lifetime MDD, and social support and response to treatment at each time point.
|
Up to 10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Carrie Daniel-MacDougall, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PA15-0336 (Other Identifier: M D Anderson Cancer Center)
- NCI-2020-08200 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cutaneous Melanoma
-
NCT03677739Active, not recruitingClinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage 0 Cutaneous Melanoma AJCC v8 | Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage IA Cutaneous Melanoma AJCC v8 | Clinical Stage IB Cutaneous Melanoma AJCC v8 | Clinical Stage II Cutaneous Melanoma AJCC v8 | Clinical Stage IIA Cutaneous Melanoma AJCC v8 | Clinical Stage IIB Cutaneous Melanoma AJCC v8
-
NCT04375527TerminatedMetastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Locally Advanced Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC V8 | Clinical Stage IV Cutaneous Melanoma AJCC V8 | Pathologic Stage III Cutaneous Melanoma AJCC V8 | Pathologic Stage IIIA Cutaneous Melanoma AJCC V8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC V8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC V8 | Pathologic Stage IIID Cutaneous Melanoma AJCC V8
-
NCT04875728Active, not recruitingClinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage IA Cutaneous Melanoma AJCC v8 | Clinical Stage IB Cutaneous Melanoma AJCC v8 | Clinical Stage II Cutaneous Melanoma AJCC v8 | Clinical Stage IIA Cutaneous Melanoma AJCC v8 | Clinical Stage IIB Cutaneous Melanoma AJCC v8 | Clinical Stage IIC Cutaneous Melanoma AJCC v8 | Pathologic Stage I Cutaneous Melanoma AJCC v8 | Pathologic Stage IA Cutaneous Melanoma AJCC v8 | Pathologic Stage IB Cutaneous Melanoma AJCC v8
-
NCT07258446SuspendedClinical Stage 0 Cutaneous Melanoma AJCC v8 | Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage II Cutaneous Melanoma AJCC v8
-
NCT02506153Active, not recruitingMetastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous Melanoma
-
NCT04516122TerminatedClinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8
-
NCT02129075CompletedMelanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Ocular Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Cutaneous Melanoma | Mucosal Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7
-
NCT04462406Active, not recruitingUnresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Advanced Melanoma | Unresectable Acral Lentiginous Melanoma
-
NCT03865212TerminatedMetastatic Melanoma | Metastatic Uveal Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8
-
NCT04990726Active, not recruitingClinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 | Melanoma Stage IV | Melanoma, Stage II
Clinical Trials on Questionnaire Administration
-
NCT04285957Completed
-
NCT02565433Terminated
-
NCT05704335RecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head Pain
-
NCT04169542RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast Carcinoma
-
NCT05035667Active, not recruitingAdvanced Malignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm
-
NCT04090619Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent Leukemia
-
NCT07199647CompletedMusculoskeletal Diseases | Chronic Pain
-
NCT05940974Active, not recruitingShoulder Arthropathy
-
NCT04152512Active, not recruitingQuality of Life | Vulvar Cancer